B2 microglobulin: Is it a reliable marker of activity in inflammatory bowel disease?

American Journal of Gastroenterology

Volumn 96, Issue 7, 2001, Pages 2177-2183

  Zissis, Miltiadis ^a,b   Afroudakis, Angelos ^c   Galanopoulos, George ^c   Palermos, Ioannis ^c   Boura, Xanthi ^c   Michopoulos, Spyros ^c   Archimandritis, Athanasios ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED;

EID: 0034933312     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02444-3     Document Type: Article

References (43)

1. Assessment of disease severity and activity in inflammatory bowel disease
2. Assessment of drug therapy in inflammatory bowel disease
3. Biological measurements of Crohn's disease activity - A reassessment
4. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis
5. Determining disease activity in inflammatory bowel disease
6. Serum concentrations of 19 serum proteins in Crohn's disease and ulcerative colitis
7. Guidelines on selection of laboratory tests for monitoring the acute phase
8. Differing acute phase responses in Crohn's disease and ulcerative colitis
9. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis
10. Disparate CD4+1amina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP manifest increased secretion of IFN-ã, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
11. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease
12. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease
13. Interrelations between interleukin-6, interleukin-1, beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease
14. Soluble interleukin-2 receptor in Crohn's disease: Relation of serum concentrations to disease activity
15. Relationship of functional and antigenic interleukin-6 to disease activity in inflammatory bowel disease
16. Eicosanoids and inflammatory bowel disease
17. Scintigraphic assessment of the severity of inflammatory bowel disease using Tc99m exametazime-labeled leucocytes
18. Correlation between faecal excretion of indium-111-labeled granulocytes and calprotectin, a granulocyte marker protein, in patients with IBD
19. Microalbuminuria correlates with intestinal histopathological grading in patients with IBD
20. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein
21. B2-microglobulin in patients and normal subjects
22. Serum levels of B2-microglobulin - A new marker of activity in Crohn's disease
23. The serum level and urinary excretion of B2-microglobulin in health and renal disease
24. Microglobulinaemia in renal failure
25. B2-microglobulin review: Its relevance in clinical oncology
26. Serum beta 2-microglobulin in acute and chronic leukemia
27. B2-microglobulin in chronic lymphocytic leukemia
28. B2-microglobulin excretion rates in patients with systemic lupus erythematosus
29. B2-microglobulin, and systemic lupus erythematosus
30. Abnormally high concentrations of B2-microglobulin in acquired immunodeficiency syndrome (AIDS) patients
31. Cortisone in ulcerative colitis. Final report on a therapeutic trial
32. Variation between observers in describing mucosal appearances in proctocolitis
33. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalzine in the treatment of mild to moderate ulcerative colitis relapse
34. An index of inflammatory activity in patients with Crohn's disease
35. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease
36. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease
37. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases
38. Assessing disease activity in Crohn's disease: Are we there yet?
39. Current concepts of the pathogenesis of inflammatory bowel disease
40. T-cell activation in Crohn's disease
41. Correlations between clinical activity, endoscopic severity and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases
42. Increased production of tumour necrosis factor-a, interleukin-1b, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease
43. Loss of interleukin-2 producing CD4+ T cells in inflammatory bowel disease